A New Study Reveals Off Label Use Of Powerful Antipsychotic Medications – (PFE, LLY, JNJ)


A new study reveals that use of powerful antipsychotic medications including Abilify and Risperdal which are used to control youngsters with attention-deficit/hyperactivity disorder (ADHD) and other behavior issues has jumped in recent years.

Antipsychotics are approved to be used for the treatment of bipolar disorder, schizophrenia, other serious mental problems and irritability concerning autism. But the U.S. Food and Drug Administration has not given them approval for ADHD or other childhood behavior problems, and their use for this purpose is considered “off label.”

Pfizer Inc. (NYSE:PFE)

Pfizer Inc. (PFE) declared that it has received an authorization conformity, under which Pfizer will acquire the limited rights to market and sell EpiPen Injection 0.3/0.15mg in Japan.

As per the terms of the contract, the exclusive rights to market and sell the next-generation EpiPen Injection in Japan will be transferred to Pfizer from Mylan Seiyaku.

In the last trading session, Pfizer Inc. (NYSE:PFE) fell -2.14% and closed at $23.74 with the total traded volume of 51.87 million shares more than the average volume of 37.53 million.

Its market capitalization is 177.77 billion and its beta value stands at 0.68 times making it less volatile stock.

Eli Lilly & Co. (NYSE:LLY)

Eli Lilly & Co. (NYSE:LLY) declined 2.20% with the closing price of $42.75. The overall volume in the last trading session was 11.00 million shares. Its fifty two week range was $33.75-$44.67.

The total market capitalization remained $49.61 billion.

LLY is ahead of its 52 week low with 33.40% and its last month price volatility remained 1.58%. Its beta coefficient was 0.67 with a target price of $40.83. In its share capital, LLY has 1.16 billion outstanding shares and all shares have been floated in market. LLY has insider ownership of 0.01% with its institutional ownership remained 74.43%.

Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE: JNJ) slipped after it announced that phase 3 clinical development of bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer’s disease is being discontinued.

Johnson & Johnson (NYSE:JNJ) dropped -0.80% to close at $68.29 and its overall traded volume was 10.37 million shares. JNJ has earnings per share of $3.14 and its price to earnings ratio ended at 21.72. Its market capitalization is 187.84 billion.


Leave a Reply

Your email address will not be published. Required fields are marked *